Related Experiment Video
Updated: May 4, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Clinical findings, pathology, and outcomes of C3GN after kidney transplantation
Ladan Zand1, Elizabeth C Lorenz1, Fernando G Cosio1
1Department of Internal Medicine, Division of Nephrology and Hypertension, and.
Insights
C3 glomerulonephritis (C3GN) frequently recurs after kidney transplantation, leading to graft failure in half of affected patients. Early diagnosis and monitoring are crucial for managing this condition post-transplant.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- C3 glomerulonephritis (C3GN) involves complement alternative pathway abnormalities and C3 deposition.
- C3GN often progresses to end-stage renal disease (ESRD).
- Outcomes of kidney transplantation in C3GN patients are not well-documented.
Purpose of the Study:
- To investigate the clinical features, pathology, and outcomes of kidney transplantation in patients with C3GN.
- To determine the recurrence rate and impact of C3GN on allograft survival.
Main Methods:
- Retrospective analysis of 21 patients with ESRD due to C3GN who underwent kidney transplantation between 1996 and 2010.
- Review of clinical data, kidney biopsy findings (native and allograft), and patient outcomes.
Main Results:
- C3GN recurred in 66.7% of transplanted patients, with a median recurrence time of 28 months.
- Graft failure occurred in 50% of patients with recurrent C3GN within a median of 77 months post-transplantation.
- Hematuria and proteinuria were common at recurrence; monoclonal gammopathy was associated with faster recurrence and graft loss.
Conclusions:
- C3GN has a high recurrence rate following kidney transplantation, significantly impacting graft survival.
- Recurrent C3GN is a major cause of graft failure in this patient population.
- Further research is needed to understand and potentially prevent C3GN recurrence post-transplant.
Abstract:
C3 glomerulonephritis (C3GN) results from abnormalities in the alternative pathway of complement, and it is characterized by deposition of C3 with absent or scant Ig deposition. In many patients, C3GN progresses to ESRD. The clinical features, pathology, and outcomes of patients with C3GN receiving kidney transplantation are unknown. Between 1996 and 2010, we identified 21 patients at our institution who received a kidney transplant because of ESRD from C3GN. The median age at the time of initial diagnosis of C3GN at kidney biopsy was 20.8 years. The median time from native kidney biopsy to dialysis or transplantation was 42.3 months. Of 21 patients, 14 (66.7%) patients developed recurrent C3GN in the allograft. The median time to recurrence of disease was 28 months. Graft failure occurred in 50% of patients with recurrent C3GN, with a median time of 77 months to graft failure post-transplantation. The remaining 50% of patients had functioning grafts, with a median follow-up of 73.9 months. The majority of patients had hematuria and proteinuria at time of recurrence. Three (21%) patients were positive for monoclonal gammopathy and had a faster rate of recurrence and graft loss. Kidney biopsy at the time of recurrence showed mesangial proliferative GN in eight patients and membranoproliferative GN in six patients. All allograft kidney biopsies showed bright C3 staining (2-3+), with six biopsies also showing trace/1+ staining for IgM and/or IgG. To summarize, C3GN recurs in 66.7% of patients, and one half of the patients experience graft failure caused by recurrence.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention

